Literature DB >> 24014585

Bilateral optic neuropathy in a patient with familial amyloidotic polyneuropathy.

Steffen Hamann1, Peter Koch Jensen, Hans Callø Fledelius.   

Abstract

Amyloidogenic transthyretin (ATTR)-related familial amyloidotic polyneuropathy (FAP) is an autosomal-dominant hereditary disease characterised by slowly progressive peripheral sensorimotor and autonomic neuropathy and tissue involvement of the heart, kidneys and central nervous system. Secondary glaucoma has been reported following intraocular surgery, but optic nerve involvement unrelated to glaucoma has not previously been described. We reported a male patient in his late 40s when deceased, who previously had a liver transplant in order to reduce the abnormal protein synthesis underlying his FAP ATTR Val30Met mutation. After 11 years of ophthalmic follow-up best-corrected visual acuity was 20/100 in his seeing eye, which further had visual field findings suggestive of optic neuropathy. This was also the diagnosis underlying the preceding insidious full loss of vision in the fellow eye, with colour Doppler imaging to support an ischaemic aetiology. To our knowledge, this is the first report of ischaemic optic neuropathy in this familial amyloid disorder.

Entities:  

Mesh:

Year:  2013        PMID: 24014585      PMCID: PMC3794177          DOI: 10.1136/bcr-2013-200445

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Central retinal vein occlusion associated with drusen of the optic disc.

Authors:  S Chern; L E Magargal; W H Annesley
Journal:  Ann Ophthalmol       Date:  1991-02

2.  Bilateral buried optic nerve drusen presenting with central retinal artery occlusion at high altitude.

Authors:  R S Newsom; D R Trew; T J Leonard
Journal:  Eye (Lond)       Date:  1995       Impact factor: 3.775

3.  Vitreous surgery in patients with primary neuropathic amyloidosis.

Authors:  O Sandgren; S Stenkula; I Dedorsson
Journal:  Acta Ophthalmol (Copenh)       Date:  1985-08

Review 4.  Color Doppler imaging of retinal diseases.

Authors:  Galina Dimitrova; Satoshi Kato
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

Review 5.  Transthyretin-related familial amyloidotic polyneuropathy.

Authors:  Yukio Ando; Masaaki Nakamura; Shukuro Araki
Journal:  Arch Neurol       Date:  2005-07

6.  Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up.

Authors:  E Ando; Y Ando; R Okamura; M Uchino; M Ando; A Negi
Journal:  Br J Ophthalmol       Date:  1997-04       Impact factor: 4.638

7.  Familial amyloidotic polyneuropathy presenting with rubeotic glaucoma.

Authors:  Anthony A S Dunlop; Stuart L Graham
Journal:  Clin Exp Ophthalmol       Date:  2002-08       Impact factor: 4.207

8.  Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His.

Authors:  G Blevins; R Macaulay; S Harder; D Fladeland; T Yamashita; M Yazaki; K Hamidi Asl; M D Benson; J R Donat
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

Review 9.  The molecular biology and clinical features of amyloid neuropathy.

Authors:  Merrill D Benson; John C Kincaid
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

10.  Vitreous surgery impact in glaucoma development in liver transplanted familial amyloidosis ATTR V30M Portuguese patients.

Authors:  Nuno M Beirão; Maria E Matos; Maria J Meneres; Idalina M Beirão; Paulo P Costa; Paulo A Torres
Journal:  Amyloid       Date:  2012-08-03       Impact factor: 7.141

View more
  2 in total

1.  Bilateral Non-arteritic Anterior Ischaemic Optic Neuropathy as the Presentation of Systemic Amyloidosis.

Authors:  M Z Kanaan; A R Lorenzi; N Thampy; R Pandit; Margaret Dayan
Journal:  Neuroophthalmology       Date:  2017-06-19

Review 2.  Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review.

Authors:  A C Martins; A M Rosa; E Costa; C Tavares; M J Quadrado; J N Murta
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.